• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    56.48 +2.50 (+4.62%)
    Streaming Delayed Price Updated: 11:35 AM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    News headline image
    Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗
    The past few years have been challenging for the biotech. 
    Via The Motley Fool
    News headline image
    The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗
    Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
    These biotech companies have catalysts ahead. 
    Via The Motley Fool
    News headline image
    CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗
    Via MarketBeat
    News headline image
    Should You Buy Shares of CRISPR Therapeutics in February? ↗
    The company could finally be ready to deliver on years of promise. 
    Via The Motley Fool
    News headline image
    The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗
    2026 could be a big year for this company. 
    Via The Motley Fool
    News headline image
    Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗
    A sales partner offered a ray of hope that this company couldn't for itself. 
    Via The Motley Fool
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    Opportunity knocks thrice for the iconic growth investor. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Forget AI Stocks: This Biotech Could Cure What AI Can't Touch ↗
    Artificial intelligence (AI) isn't the only industry with explosive growth potential. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗
    Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    News headline image
    Cathie Wood&#39;s Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops ↗
    Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core... 
    Via Benzinga
    News headline image
    2 Biotech Stocks That Could Soar This Year ↗
    And, if all goes well, over the next five years as well. 
    Via The Motley Fool
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗
    There are some risks to consider before jumping on the bandwagon. 
    Via The Motley Fool
    News headline image
    The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
    On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),... 
    Via PredictStreet
    Topics Economy
    News headline image
    Is CRISPR Therapeutics Stock Yesterday's News? ↗
    The biotech sells blood disorders treatment, Casgevy. 
    Via The Motley Fool
    News headline image
    3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
    All three companies' businesses are on the verge of long-term growth explosions. 
    Via The Motley Fool
    News headline image
    Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗
    Next year could be crucial for the company as sales for its only approved treatment could take off. 
    Via The Motley Fool
    News headline image
    2 Growth Stocks to Invest $1,000 in Right Now ↗
    These stocks have promising assets in their portfolios that could help make their valuations soar in the future. 
    Via The Motley Fool
    News headline image
    From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
    Issued on behalf of Avant Technologies Inc. 
    From USA News Group
    Via GlobeNewswire
    News headline image
    2 Monster Stocks in the Making to Buy and Hold ↗
    The next 12 months will tell us more about their prospects. 
    Via The Motley Fool
    News headline image
    12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗
    The following players span a variety of industries, so if you pick up more than one, you may gain in diversification. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Healthcare Stocks to Buy Ahead of the New Year ↗
    These companies could innovate their way to success. 
    Via The Motley Fool
    News headline image
    2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
    This juicy upside potential comes at a cost. 
    Via The Motley Fool
    News headline image
    Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗
    This company's first product has started to generate revenue. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    The Best Stocks to Buy With $1,000 Right Now ↗
    It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction. 
    Via The Motley Fool
    Topics Artificial Intelligence Energy
    News headline image
    3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗
    These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run. 
    Via The Motley Fool
    News headline image
    Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
    Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of... 
    Via MarketMinute
    News headline image
    Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
    These stocks both have advanced in the double-digits in recent months. 
    Via The Motley Fool
    News headline image
    1 Underrated Stock That Could Soar by 58%, According to Wall Street ↗
    This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy? 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.